The weight-loss company launched a program that gives some users access to drugs known as GLP-1s.The popular weight-loss app Noom quietly launched a new program that offers some users access to prescription anti-obesity medications.
Called Noom Clinical, the program is meant to"build additional support" for app users, a company spokesperson said in a statement to Insider. Users who meet certain medical-eligibility criteria are evaluated by a clinician and could be prescribed medicines that help with weight loss, including trendy GLP-1 agonists or other medicines. GLP-1s, such as Ozempic and Wegovy, are a class of drugs that have"While medication is not appropriate for all Noom Clinical users, the program can offer a better chance at long-term weight loss success utilizing medication to optimize biology for those who qualify," the spokesperson said.
Finance Finance Latest News, Finance Finance Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Employers grapple with cost, coverage of Ozempic, Wegovy weight-loss drugsWorkers are clamoring for pricey new weight-loss drugs like Ozempic. Companies are grappling with how to respond. Have a prescription for Ozempic? Order online & SAVE ➧ ➧ SAVE 10% on first order with coupon code: FIRST10
Source: BusinessInsider - 🏆 729. / 51 Read more »